Among patients with nondiabetic CKD, SGLT2 inhibitors have favorable effects in IgA nephropathy, whereas their efficacy is limited in focal segmental glomerulosclerosis and uncertain in autosomal dominant polycystic kidney disease and autoimmune-related nephritis. This evidence concerns the gene SLC5A2 and focal segmental glomerulosclerosis.